The list of the drugs under clinical trial for the treatment of CML that are BCR/ABL-positive at Phase 3 or Phase 4 is mentioned in Table 1. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.